logo-loader

Sinovac receives positive preliminary results for HFMD vaccine

Last updated: 11:15 10 Mar 2011 EST, First published: 12:15 10 Mar 2011 EST

no_picture_pai

China's Sinovac Biotech (NASDAQ:SVA) said Thursday that it has received positive preliminary results from a phase one clinical trial for its vaccine against hand, foot and mouth disease (HFMD).

The early results for the EV71 vaccine in adults showed a good safety and tolerance profile, according to the company. The phase one placebo-controlled study is on track to enroll 168 healthy volunteers in three different age groups: adults, young children and infants.

Sinovac said that it has now begun testing on the young children and infant groups, from which results are expected in the coming months.

The company received approval from the China State Food and Drug Administration to begin clinical trials for the vaccine last December.

Sinovac is currently working on developing and manufacturing vaccines against hepatitis A, season influenza, bird flu, and H1N1. In 2009, the company was the first worldwide to receive approval for its H1N1 vaccine, PANFLU.1.

ARway.ai announces multiple new SaaS developer contracts in both the United...

ARway.ai (CSE:ARWY, OTCQB:ARWYF) Chief Executive Officer Evan Gappelberg joined Steve Darling from Proactive to announce multiple new SaaS developer sign-ups for its augmented reality experience platform, focusing on AR indoor navigation. These partnerships represent significant milestones in...

52 minutes ago